JP2005527582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527582A5 JP2005527582A5 JP2003583374A JP2003583374A JP2005527582A5 JP 2005527582 A5 JP2005527582 A5 JP 2005527582A5 JP 2003583374 A JP2003583374 A JP 2003583374A JP 2003583374 A JP2003583374 A JP 2003583374A JP 2005527582 A5 JP2005527582 A5 JP 2005527582A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- use according
- intervals
- dose
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 claims 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 235000012000 cholesterol Nutrition 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 3
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 208000019553 vascular disease Diseases 0.000 claims 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000004026 tunica intima Anatomy 0.000 claims 2
- 230000036269 ulceration Effects 0.000 claims 2
- 239000002691 unilamellar liposome Substances 0.000 claims 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 102000006996 Aryldialkylphosphatase Human genes 0.000 claims 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000014882 Carotid artery disease Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010021024 Hypolipidaemia Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 1
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 claims 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229960005069 calcium Drugs 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims 1
- 229940093541 dicetylphosphate Drugs 0.000 claims 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- -1 fibrate Substances 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 230000010030 glucose lowering effect Effects 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37040902P | 2002-04-05 | 2002-04-05 | |
| PCT/US2003/010339 WO2003086351A1 (en) | 2002-04-05 | 2003-04-04 | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527582A JP2005527582A (ja) | 2005-09-15 |
| JP2005527582A5 true JP2005527582A5 (enExample) | 2006-04-27 |
Family
ID=29250522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003583374A Pending JP2005527582A (ja) | 2002-04-05 | 2003-04-04 | 疾患を治療または予防するための組成物および特定サイズのリポソームの投与方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20040009216A1 (enExample) |
| EP (1) | EP1501482A1 (enExample) |
| JP (1) | JP2005527582A (enExample) |
| KR (1) | KR20050009988A (enExample) |
| CN (1) | CN1655764A (enExample) |
| AP (1) | AP2004003157A0 (enExample) |
| AU (1) | AU2003230800A1 (enExample) |
| BR (1) | BR0309030A (enExample) |
| CA (1) | CA2480763A1 (enExample) |
| CR (1) | CR7563A (enExample) |
| EA (1) | EA007986B1 (enExample) |
| EC (1) | ECSP045409A (enExample) |
| HR (1) | HRP20040915A2 (enExample) |
| IL (1) | IL164370A0 (enExample) |
| IS (1) | IS7493A (enExample) |
| MA (1) | MA27298A1 (enExample) |
| MX (1) | MXPA04009692A (enExample) |
| NO (1) | NO20044751L (enExample) |
| NZ (1) | NZ535900A (enExample) |
| OA (1) | OA12799A (enExample) |
| PL (1) | PL372689A1 (enExample) |
| RS (1) | RS87704A (enExample) |
| TN (1) | TNSN04190A1 (enExample) |
| UA (1) | UA80121C2 (enExample) |
| WO (1) | WO2003086351A1 (enExample) |
| ZA (1) | ZA200407947B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037271A1 (en) * | 2002-10-25 | 2004-05-06 | Vasogen Ireland Limited | Cyclooxygenase regulation with ps liposomes |
| AU2003275842A1 (en) * | 2002-10-25 | 2004-05-13 | Vasogen Ireland Limited | Cyclooxygenase regulation with pg liposomes |
| US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| MXPA06000805A (es) * | 2003-07-21 | 2006-04-18 | Vasogen Ireland Ltd | Liposomas que contienen grupos de glicerol fosfato para tratar una condicion inflamatoria aguda. |
| US20080260861A1 (en) * | 2004-04-07 | 2008-10-23 | The General Hospital Corporation | Modulating Lymphatic Function |
| JP2008521818A (ja) * | 2004-11-23 | 2008-06-26 | メデイカル・カレツジ・オブ・ジヨージア | ケラチノサイト機能を調節するための方法および組成物 |
| KR100891595B1 (ko) * | 2005-02-28 | 2009-04-03 | 주식회사 케이티앤지 | 혈액 단백질의 삼출을 감소시키는 조성물 |
| KR100768265B1 (ko) * | 2005-11-10 | 2007-10-17 | 한국화학연구원 | 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법 |
| JP4395658B2 (ja) * | 2005-11-17 | 2010-01-13 | エムジーファーマ株式会社 | コレステロール再上昇抑制用組成物およびその用法 |
| US8697120B2 (en) * | 2006-05-01 | 2014-04-15 | Johns Hopkins University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| ES2874149T3 (es) * | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
| EP2245039A4 (en) * | 2008-01-31 | 2012-06-06 | Alnylam Pharmaceuticals Inc | OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN |
| US20100267806A1 (en) * | 2009-03-12 | 2010-10-21 | David Bumcrot | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
| KR102229618B1 (ko) | 2009-05-05 | 2021-03-18 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
| WO2010140061A2 (en) * | 2009-06-03 | 2010-12-09 | John Charles Mayo | Formulations for the treatment of deep tissue pain |
| NZ622843A (en) * | 2009-06-10 | 2015-10-30 | Tekmira Pharmaceuticals Corp | Improved lipid formulation |
| WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
| NZ597504A (en) * | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
| WO2011059262A2 (ko) * | 2009-11-13 | 2011-05-19 | 경북대학교 산학협력단 | 사멸세포 표적 펩타이드, 표지물질 및 치료제를 포함하는 리포솜의 아포토시스 관련 질환의 예방, 치료 또는 치료진단을 위한 용도 |
| CN108114285A (zh) | 2011-07-15 | 2018-06-05 | 纽斯尔特科学公司 | 用于调节代谢途径的组合物和方法 |
| CN104918610B (zh) | 2012-11-13 | 2018-04-10 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
| PT2929031T (pt) | 2012-12-05 | 2018-01-19 | Alnylam Pharmaceuticals Inc | Composições de irna de pcsk9 e métodos de seu uso |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| CN104422750B (zh) * | 2013-09-05 | 2016-02-10 | 中国科学院大连化学物理研究所 | 一种烟叶中磷脂酰乙醇胺与甘油三酯含量的检测方法 |
| WO2015108134A1 (ja) * | 2014-01-17 | 2015-07-23 | 株式会社西崎創薬研究所 | Ｇｌｕｔ４エンドサイトーシス抑制剤 |
| CN110279654B (zh) * | 2019-07-22 | 2023-02-03 | 苏州大学附属第一医院 | 缓释阿司匹林脂质体水凝胶、制备方法及其在制备治疗复发性腰椎间盘突出症药物中的应用 |
| WO2022118913A1 (ja) * | 2020-12-04 | 2022-06-09 | 株式会社レグイミューン | 体内動態が改善されたＣＤ１ｄリガンド化合物含有リポソーム製剤 |
| US12133966B2 (en) | 2020-12-22 | 2024-11-05 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| US11806507B2 (en) | 2020-12-22 | 2023-11-07 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| AU2021409558A1 (en) * | 2020-12-22 | 2023-07-20 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion |
| WO2025159416A1 (ko) * | 2024-01-22 | 2025-07-31 | 연세대학교 산학협력단 | 단핵구에 탑재되는 리포좀을 포함하는 약물 전달체 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| JPS5348976A (en) * | 1976-10-18 | 1978-05-02 | Nippon Zeon Co Ltd | Mass transfer apparatus of hollow fiber type |
| US4186183A (en) * | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4247393A (en) * | 1979-01-11 | 1981-01-27 | Wallace Richard A | Hemodialysis assist device |
| US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| DE3276390D1 (en) * | 1981-09-10 | 1987-06-25 | Intermedicat Gmbh | Method for the selective extracorporeal precipitation of low-density lipoproteins from serum or plasma |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4532089A (en) * | 1984-01-14 | 1985-07-30 | Northwestern University | Method of preparing giant size liposomes |
| US4663167A (en) * | 1984-04-16 | 1987-05-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment of disseminated fungal infections in mammals |
| US4978654A (en) * | 1984-04-16 | 1990-12-18 | Board Of Regents, The University Of Texas System | Composition and method for treatment of disseminated fungal infections in mammals |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| ATE78158T1 (de) * | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| US4774085A (en) * | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
| US5204112A (en) * | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
| US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
| US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US5258499A (en) * | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5219994A (en) * | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
| US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| DK0469082T3 (da) * | 1989-04-18 | 1995-08-28 | Nexstar Pharmaceuticals Inc | Liposomal målretning mod iskæmiske væv |
| US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE4018767A1 (de) * | 1990-06-12 | 1991-12-19 | Braun Melsungen Ag | Wirkstofffreie liposomen zur behandlung von atherosklerose |
| US5231090A (en) * | 1990-07-30 | 1993-07-27 | University Of Miami | Treatment for hypercholesterolemia |
| US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
| JPH04305879A (ja) * | 1990-09-12 | 1992-10-28 | Fuji Electric Co Ltd | ディスク記憶装置のヘッド操作用可動体の拘束装置 |
| US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
| US5405832A (en) * | 1991-11-27 | 1995-04-11 | Immtech International Inc. | Method of treating non-streptococcal bacterial infections |
| US5219888A (en) * | 1992-03-31 | 1993-06-15 | American Cyanamid Company | Use of retinoids for the treatment of coronary artery disease |
| US5250060A (en) * | 1992-06-26 | 1993-10-05 | Carbo Paul L | Angioplasty apparatus |
| US5637315A (en) * | 1993-01-04 | 1997-06-10 | Thomas Jefferson University | Treatment of disease states induced by oxidative stress |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
| US6139871A (en) * | 1995-07-26 | 2000-10-31 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US5746223A (en) * | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
| US5599306A (en) * | 1994-04-01 | 1997-02-04 | Localmed, Inc. | Method and apparatus for providing external perfusion lumens on balloon catheters |
| US5622715A (en) * | 1994-06-10 | 1997-04-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of improving renal function |
| US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5674488A (en) * | 1994-10-07 | 1997-10-07 | Reich; John J. | Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol |
| CA2206289A1 (en) * | 1994-11-23 | 1996-05-30 | Kimberly-Clark Worldwide, Inc. | Absorbent article having a composite absorbent core |
| US5489611A (en) * | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
| US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5741514A (en) * | 1995-08-31 | 1998-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for reducing serum lipoprotein(a) concentration |
| AU759964B2 (en) * | 1995-10-11 | 2003-05-01 | Esperion Luv Development, Inc. | Liposomal compositions and methods of using them |
| US5846691A (en) * | 1996-07-08 | 1998-12-08 | Polyfibron Technologies, Inc. | Composite relief image printing plates and methods for preparing same |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| CN1329359C (zh) * | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
| WO2000069412A1 (en) * | 1999-05-14 | 2000-11-23 | Esperion Luv Development, Inc. | Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| BR0212866A (pt) * | 2001-09-28 | 2004-09-14 | Esperion Therapeutics Inc | Métodos de produzir uma suspensão de vesìcula e lipossomas e dispositivo para extrudar uma suspensão aquosa de lipìdeos a alta pressão |
-
2003
- 2003-03-31 US US10/403,402 patent/US20040009216A1/en not_active Abandoned
- 2003-04-04 BR BR0309030-2A patent/BR0309030A/pt not_active IP Right Cessation
- 2003-04-04 EA EA200401317A patent/EA007986B1/ru not_active IP Right Cessation
- 2003-04-04 NZ NZ535900A patent/NZ535900A/en unknown
- 2003-04-04 KR KR10-2004-7015874A patent/KR20050009988A/ko not_active Ceased
- 2003-04-04 CN CNA038125668A patent/CN1655764A/zh active Pending
- 2003-04-04 JP JP2003583374A patent/JP2005527582A/ja active Pending
- 2003-04-04 WO PCT/US2003/010339 patent/WO2003086351A1/en not_active Ceased
- 2003-04-04 CA CA002480763A patent/CA2480763A1/en not_active Abandoned
- 2003-04-04 MX MXPA04009692A patent/MXPA04009692A/es unknown
- 2003-04-04 OA OA1200400268A patent/OA12799A/en unknown
- 2003-04-04 HR HR20040915A patent/HRP20040915A2/hr not_active Application Discontinuation
- 2003-04-04 AP APAP/P/2004/003157A patent/AP2004003157A0/en unknown
- 2003-04-04 UA UA20041108994A patent/UA80121C2/uk unknown
- 2003-04-04 RS YU87704A patent/RS87704A/sr unknown
- 2003-04-04 IL IL16437003A patent/IL164370A0/xx unknown
- 2003-04-04 AU AU2003230800A patent/AU2003230800A1/en not_active Abandoned
- 2003-04-04 PL PL03372689A patent/PL372689A1/xx not_active Application Discontinuation
- 2003-04-04 EP EP03723897A patent/EP1501482A1/en not_active Withdrawn
-
2004
- 2004-10-01 ZA ZA200407947A patent/ZA200407947B/en unknown
- 2004-10-04 TN TNP2004000190A patent/TNSN04190A1/en unknown
- 2004-10-04 MA MA27886A patent/MA27298A1/fr unknown
- 2004-10-08 IS IS7493A patent/IS7493A/is unknown
- 2004-11-02 CR CR7563A patent/CR7563A/es not_active Application Discontinuation
- 2004-11-02 NO NO20044751A patent/NO20044751L/no not_active Application Discontinuation
- 2004-11-04 EC EC2004005409A patent/ECSP045409A/es unknown
-
2008
- 2008-02-21 US US12/070,949 patent/US20080213351A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527582A5 (enExample) | ||
| JP2005527582A (ja) | 疾患を治療または予防するための組成物および特定サイズのリポソームの投与方法 | |
| KR101437338B1 (ko) | 서방형 항감염제 | |
| US5523297A (en) | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines | |
| JP6087862B2 (ja) | リポソームアミカシン処方物による肺疾患の治療方法 | |
| US20080269111A1 (en) | Method of treating dyslipidemic disorder | |
| JP2012229255A (ja) | 活性成分を含有するカチオンリポソームの投与方法 | |
| UA46069C2 (uk) | Спосіб нормалізації ліпопротеїдного профілю плазми крові у ссавця, фармацевтична композиція для його здійснення, спосіб запобігання і/або лікування захворювання, пов'язаного з дисфункцією ендотелію, спосіб відновлення активності, обумовленої ендогенним судинним ендотелієм, спосіб стабілізації атеросклеротичного ураження і запобігання розриву бляшок у ссавця | |
| US20250120949A1 (en) | Use of spla2 inhibitors to treat envenomation by snakes and wasps | |
| Atar et al. | Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances | |
| US8143265B2 (en) | Method of treating atherosclerosis | |
| US20240299414A1 (en) | Subcutaneous or intramuscular injection formulations of iloprost | |
| US20230372296A1 (en) | Compositions and methods for anxiety disorder treatment | |
| US20250120950A1 (en) | Use of spla2 inhibitors to treat hymenoptera envenomation, hemolysis, and kidney disease, and to protect blood from osmotic fragility | |
| CA3022013C (en) | Secreted pla2 inhibitors for immediate treatment of hymenoptera envenomation | |
| DE60305592T2 (de) | Liposomenhaltiges Mittel zur Behandlung Gefässerkrankungen | |
| HK40006646A (en) | Pla2 inhibitors for immediate treatment of hymenoptera envenomation and other conditions caused by histamine release | |
| BR112018072162B1 (pt) | Uso de um inibidor de molécula pequena da fosfolipase a2 (pla2) | |
| Wibel et al. | Keywords Phospholipids Vaccines Depot injectables Pulmonary dosage forms Natural and Synthetic Phospholipids For Vaccines and Other Complex Drug Delivery Systems–Part 2 |